BioCardia Files Routine 8-K with Financials
Ticker: BCDA · Form: 8-K · Filed: Dec 17, 2024 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, financials, regulatory
Related Tickers: BCDA
TL;DR
BioCardia filed a routine 8-K with financials, no major news.
AI Summary
On December 17, 2024, BioCardia, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a specific material event. No new material agreements, executive changes, or significant financial transactions were detailed in the provided excerpt.
Why It Matters
This filing indicates BioCardia, Inc. is providing standard financial updates and exhibits to the SEC, which is a normal part of regulatory compliance for public companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard regulatory submission of financial statements and exhibits, with no indication of new risks or material adverse events.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- December 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38999 (filing_number) — SEC File Number
- 23-2753988 (tax_id) — IRS Employer Identification No.
- 320 Soquel Way Sunnyvale, California 94085 (address) — Address of principal executive offices
- Tiger X Medical, Inc. (company) — Former company name
- Cardo Medical, Inc. (company) — Former company name
- CLICKNSETTLE COM INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing by BioCardia, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 17, 2024.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 17, 2024.
In which state is BioCardia, Inc. incorporated?
BioCardia, Inc. is incorporated in Delaware.
What is BioCardia, Inc.'s principal executive office address?
BioCardia, Inc.'s principal executive office is located at 320 Soquel Way, Sunnyvale, California 94085.
Has BioCardia, Inc. operated under any previous names?
Yes, BioCardia, Inc. has operated under the former names Tiger X Medical, Inc., Cardo Medical, Inc., and CLICKNSETTLE COM INC.
Filing Stats: 418 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-12-17 07:00:13
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20241217_8k.htm (8-K) — 28KB
- ex_758314.htm (EX-99.1) — 10KB
- 0001437749-24-037688.txt ( ) — 170KB
- bcda-20241217.xsd (EX-101.SCH) — 3KB
- bcda-20241217_def.xml (EX-101.DEF) — 11KB
- bcda-20241217_lab.xml (EX-101.LAB) — 15KB
- bcda-20241217_pre.xml (EX-101.PRE) — 11KB
- bcda20241217_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 17, 2024, BioCardia, Inc. (the "Company") issued a press release announcing the commercial availability of its Morph DNA steerable introducer product family, current utilized in the Company's ongoing clinical trials. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 BioCardia, Inc. press release dated December 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document.)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: December 17, 2024